论文部分内容阅读
胰腺神经内分泌肿瘤(P-NEN)少见,仅占所有胰腺肿瘤的1%～2%,估计其年发病率为(0.2～2.0)/100万人。以往的外科手术资料显示,30%～40%的P-NEN为无功能性肿瘤。但随着影像学技术的进步,偶然检出的无功能性P-NEN显著增加,占所有P-NEN的50%～80%。近年来,对于胃肠胰腺神经内分泌肿瘤(GEP-NEN)的基础和临床研究均取得了较大进展。本文仅就P-NEN的命名、分类、靶向药物治疗和第八届欧洲神经内分泌肿瘤大会中有关P-NEN的研究新进展作一介绍。
Pancreatic neuroendocrine tumors (P-NEN) rare, accounting for only 1% to 2% of all pancreatic tumors, the estimated annual incidence of (0.2 ~ 2.0) / 100 million. Surgical data shows that 30% to 40% of P-NEN is a non-functional tumor. However, with the progress of imaging technology, the non-functional P-NEN detected by chance increased significantly, accounting for 50% -80% of all P-NEN. In recent years, great progress has been made in the basic and clinical researches of gastrointestinal pancreatic neuroendocrine tumors (GEP-NEN). This article describes only the P-NEN nomenclature, classification, targeted drug therapy and the progress of the P-NEN research in the Eighth European Conference on Neuroendocrine Tumors.